Trial Profile
A Phase II, Open Label, Active Control, Multi-National, Multi-Centre, Randomized, Parallel Group Study Assessing Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of CAM2032 (Leuprolide Acetate FluidCrystal Injection Depot Once Monthly) After Repeat Doses of 3.75 mg and 7.5 mg of Leuprolide Acetate vs. Eligard 7.5 mg in Patients With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Camurus
- 21 Jun 2016 According to a Camurus media release, detailed results from the trial will be presented in a future publication.
- 21 Jun 2016 Results (n=51) published in a Camurus media release.
- 02 Mar 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.